Aktive Positionen von Melanie Kelly
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
Panag Pharma, Inc.
 Panag Pharma, Inc. Pharmaceuticals: MajorHealth Technology Panag Pharma, Inc. engages in the development of novel cannabinoid-based formulations for the treatment of pain and inflammation. Its product Topical A, provides a new approach to the treatment of chronic pain and inflammation. The company was founded by Mary Lynch, Melanie Kelly, Christian Lehmann, and Orlando Hung and is headquartered in Halifax, Canada. | Technik-/Wissenschafts-/F&E-Leiter | - | - |
| Gründer | - | - |
Karriereverlauf von Melanie Kelly
Ehemalige bekannte Positionen von Melanie Kelly
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
TALLC Corp., Inc.
 TALLC Corp., Inc. Pharmaceuticals: MajorHealth Technology TALLC Corp, Inc. operates as a pre-clinical stage pharmaceutical company. It focuses on the development of TA-A001, a novel endocannabinoid CB2 receptor activator with potent anti-inflammatory analgesic properties. The company was founded by Damon Smith, Melanie Kelly and Guy Chamberland and is headquartered in Laval, Canada. | Gründer | - | - |
Statistik
International
| Kanada | 3 |
Operativ
| Founder | 2 |
| Chief Tech/Sci/R&D Officer | 1 |
Sektoral
| Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Panag Pharma, Inc.
Panag Pharma, Inc. Pharmaceuticals: MajorHealth Technology Panag Pharma, Inc. engages in the development of novel cannabinoid-based formulations for the treatment of pain and inflammation. Its product Topical A, provides a new approach to the treatment of chronic pain and inflammation. The company was founded by Mary Lynch, Melanie Kelly, Christian Lehmann, and Orlando Hung and is headquartered in Halifax, Canada. | Health Technology |
TALLC Corp., Inc.
TALLC Corp., Inc. Pharmaceuticals: MajorHealth Technology TALLC Corp, Inc. operates as a pre-clinical stage pharmaceutical company. It focuses on the development of TA-A001, a novel endocannabinoid CB2 receptor activator with potent anti-inflammatory analgesic properties. The company was founded by Damon Smith, Melanie Kelly and Guy Chamberland and is headquartered in Laval, Canada. | Health Technology |
- Börse
- Insiders
- Melanie Kelly
- Erfahrung
